# A translation fund for academic surgical devices and radiotherapy technology

Source: https://onco.cc/ideas/idea-fund-device-and-technique-translation-fund/  
OnCo record `idea-fund-device-and-technique-translation-fund` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

New surgical tools, imaging probes and radiotherapy hardware invented in universities rarely attract investors. A dedicated fund would pay for prototyping, safety testing and first-in-human studies.

## Summary

A fund for academic devices and techniques in cancer surgery and radiotherapy: intraoperative imaging probes, margin-assessment tools, low-cost brachytherapy applicators, FLASH-capable beam systems, adaptive planning software, robotic instruments. It pays for design-for-manufacture, ISO 13485 quality systems, biocompatibility and safety testing and IDEAL-framework early studies. Device venture capital is thin outside cardiology and orthopaedics, and academic engineering groups have no path to first-in-human without it. The fund would work with translational institutes and the surgical and radiotherapy trials networks proposed elsewhere in this wave.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A device translation fund of $50 million over five years brings at least fifteen academic cancer surgery or radiotherapy technologies to first-in-human evaluation and at least five to a randomised or IDEAL stage 3 study, compared with a handful in the preceding five years.
- Rationale: Fluorescence-guided surgery agents and intraoperative margin tools have taken well over a decade to reach approval largely for lack of translational funding; where public funding existed (for example the UK's NIHR i4i programme) academic devices reached patients. Oncology devices are a market failure because they are hard to patent broadly and slow to reimburse.
- Proposed test: Fund a first cohort of ten technologies and track time to first-in-human, regulatory milestones and subsequent trials against a matched set of unfunded academic devices.
- Maturity: speculative
- Actor: philanthropy

## Sources

- Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008): https://doi.org/10.1038/453840a

## Connected records

- ideas: [A permanently funded international network for randomised cancer surgery trials](https://onco.cc/ideas/idea-fund-surgical-trials-network/), [A pragmatic trial network for intraoperative margin tools, paid on margin reduction](https://onco.cc/ideas/idea-fund-intraoperative-imaging-trials/), [Mandatory staged registries for new surgical techniques before wide adoption](https://onco.cc/ideas/idea-fund-device-technique-registry/)
- technologies: [Brachytherapy](https://onco.cc/technologies/brachytherapy/), [FLASH radiotherapy](https://onco.cc/technologies/flash-rt/), [Fluorescence-guided surgery](https://onco.cc/technologies/fluorescence-guided-surgery/), [MR-guided adaptive radiotherapy](https://onco.cc/technologies/mr-linac/), [Optical & fluorescence imaging](https://onco.cc/technologies/optical-imaging/)
- bottlenecks: [Surgery and radiotherapy cure most, get least](https://onco.cc/bottlenecks/b-surgery-radiation-innovation/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)
- key papers: [Translational research: crossing the valley of death](https://onco.cc/key-papers/paper-butler-nature/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-device-and-technique-translation-fund.json